Correct Answer: A. Angiotensin – converting enzyme
ACE inhibitors are absolutely contraindicated in pregnancy and must be discontinued before conception. They cause fetal renal dysgenesis, oligohydramnios, intrauterine growth restriction (IUGR), and fetal death, particularly in the second and third trimesters. The mechanism involves reduced fetal renal perfusion pressure, leading to acute kidney injury and permanent renal damage. Indian guidelines (ICMR, IAP) and international consensus (FDA Category D/X) mandate ACE inhibitor avoidance throughout pregnancy. The teratogenic risk is highest when exposure occurs during organogenesis (weeks 2–8) and renal development (weeks 8–16). Even short-term exposure in early pregnancy carries significant risk. A woman planning conception must switch to safer alternatives at least 1–2 months before attempting pregnancy to allow washout and establish alternative therapy. This is a non-negotiable safety principle in preconception counseling for any woman of reproductive age on ACE inhibitors.
Why the other options are wrong
B. Alpha methyldopa — Alpha methyldopa is the gold standard antihypertensive in pregnancy and is safe throughout all trimesters. It has the longest safety record in Indian obstetric practice and is explicitly recommended by IAP and ICMR guidelines. No teratogenic or fetotoxic effects have been documented. It is the first-line agent for chronic hypertension in pregnancy and should be continued, not discontinued. C. Calcium channel blockers — Calcium channel blockers (particularly nifedipine) are safe in pregnancy and are second-line agents after methyldopa for chronic hypertension management. They do not cause fetal renal dysgenesis or other major teratogenic effects. Extended-release nifedipine is widely used in Indian obstetric units for both chronic hypertension and acute blood pressure control in pregnancy. They should be continued, not discontinued. D. Labetalol — Labetalol is a combined alpha and beta-blocker that is safe in pregnancy and is recommended as a first-line agent in many international guidelines and Indian practice. It has no known teratogenic effects and is particularly useful for acute hypertensive episodes in pregnancy. It is often used as an alternative to methyldopa and should be continued, not discontinued.
High-Yield Facts
- ACE inhibitors and ARBs are absolutely contraindicated in pregnancy (FDA Category D/X); cause fetal renal dysgenesis, oligohydramnios, IUGR, and fetal death.
- Methyldopa is the gold-standard first-line antihypertensive in pregnancy; safe throughout all trimesters with longest safety record.
- Nifedipine (extended-release) is second-line in pregnancy; safe and effective for both chronic hypertension and acute BP control.
- Labetalol is a safe first-line alternative in pregnancy; combined alpha-beta blocker with no teratogenic effects.
- Preconception counseling requires switching from ACE-I/ARB to methyldopa or nifedipine at least 1–2 months before conception to allow washout.
- Thiazide diuretics are relatively safe but less preferred; avoid in pregnancy due to metabolic effects and reduced placental perfusion.
Mnemonics
SAFE in Pregnancy (Antihypertensives) Safe = Methyldopa (gold standard), Alternative = Nifedipine (CCB), First-line = Labetalol, Extra = Hydralazine (acute). Avoid ACE-I, ARBs, and ACE inhibitors entirely. ACE-I TERATOGENIC (Pregnancy Risk) Acute kidney injury, Cardiac defects (rare), Excess fetal death | Teratogenic in 2nd/3rd trimester, Early organogenesis risk, Renal dysgenesis, Amnios reduction, TIUGR, Oliguria, Growth restriction, Embryonic loss, Nephrotoxicity, Intrauterine death, C = Contraindicated absolutely.
NBE Trap
NBE pairs ACE inhibitors with "safe in pregnancy" or "can be continued" to trap students who confuse them with methyldopa or who underestimate the severity of ACE-I teratogenicity. The question tests whether students know the absolute contraindication versus relative safety of other agents.
Clinical Pearl
In Indian obstetric practice, any woman on ACE-I/ARB presenting for preconception counseling must be switched immediately to methyldopa or nifedipine. Delayed counseling or continued ACE-I use during conception attempts is a common cause of preventable fetal morbidity and mortality in resource-limited settings.
_Reference: KD Tripathi Pharmacology Ch. 31 (Antihypertensives in Pregnancy); Harrison Ch. 295 (Hypertension in Pregnancy); DC Dutta Obstetrics Ch. 8 (Medical Disorders in Pregnancy)_